The FDA just approved tirzepatide for type 2 diabetes. It is a GIP/GLP-1 agonist (activator). CCL5 (RANTES) downregulates GLP-1 and of course CCR5 blockade by leronlimab would upregulate it. It would be brilliant if current management ever did anything about it.

https://citeseerx.ist.psu.edu/viewdoc/downloa...p;type=pdf